Raymond James Initiates Coverage On Curis with Outperform Rating, Announces Price Target of $15
Raymond James analyst Dane Leone initiates coverage on Curis (NASDAQ:CRIS) with a Outperform rating and announces Price Target of $15.
Return on Capital Employed Overview: Curis
Pulled from Benzinga Pro data Curis (NASDAQ:CRIS) reported Q2 sales of $2.29 million. Earnings fell to a loss of $10.65 million, resulting in a 21.02% decrease from last quarter.
Recap: Curis Q2 Earnings
Shares of Curis (NASDAQ:CRIS) were flat in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 29.41% year over year to ($0.12), which missed the estimate of ($0.11).
Curis Q2 EPS $(0.12) Misses $(0.11) Estimate, Sales $2.29M Miss $2.48M Estimate
Curis (NASDAQ:CRIS) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 29.41 percent increase over losses of $(0.17) per share from the same
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.
Analyzing Curis’s Unusual Options Activity
Shares of Curis (NASDAQ:CRIS) saw some unusual options activity on Thursday. Following the unusual option alert, the stock price moved up to $7.66.
Kymera Therapeutics’ KT-413 Shows Encouraging Preclinical Anti-Cancer Activity
Kymera Therapeutics Inc (NASDAQ:KYMR) has announced new preclinical data on its IRAKIMiD degrader KT-413’s potential as both a monotherapy and in…
64 Biggest Movers From Friday
Gainers
Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share.